Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Dietary Mannan Oligosaccharides: Counteracting the Side Effects of Soybean Meal Oil Inclusion on European Sea Bass (Dicentrarchus labrax) Gut Health and Skin Mucosa Mucus Production?

Torrecillas S, Montero D, Caballero MJ, Pittman KA, Custódio M, Campo A, Sweetman J, Izquierdo M.

Front Immunol. 2015 Aug 5;6:397. doi: 10.3389/fimmu.2015.00397. eCollection 2015.

2.

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.

Barbhaiya RH, Marathe PH, Greene DS, Mayol RF, Shukla UA, Gammans RR, Pittman KA, Robinson D.

J Clin Pharmacol. 1995 Oct;35(10):974-84.

PMID:
8568015
3.

Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.

Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, et al.

J Infect Dis. 1994 Jun;169(6):1250-5.

PMID:
8195601
5.

The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.

Shyu WC, Morgenthien EA, Pittman KA, Barbhaiya RH.

Eur J Clin Pharmacol. 1994;47(1):57-60.

PMID:
7988625
6.

Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.

Barbhaiya RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, Gammans RE.

Eur J Clin Pharmacol. 1994;46(1):41-7.

PMID:
7911763
7.

Multiple-dose phase I study of transnasal butorphanol.

Shyu WC, Pittman KA, Robinson D, Barbhaiya RH.

Clin Pharmacol Ther. 1993 Jul;54(1):34-41.

PMID:
8330463
8.

Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.

Shyu WC, Mayol RF, Pfeffer M, Pittman KA, Gammans RE, Barbhaiya RH.

Biopharm Drug Dispos. 1993 Jul;14(5):371-9.

PMID:
8218955
9.

Effect of food on the bioavailability of gepirone in humans.

Tay LK, Sciacca MA, Sostrin MB, Farmen RH, Pittman KA.

J Clin Pharmacol. 1993 Jul;33(7):631-5.

PMID:
8103528
10.

Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.

Shukla UA, Marathe PH, Pittman KA, Barbhaiya RH.

Drug Metab Dispos. 1993 May-Jun;21(3):502-7.

PMID:
8100508
11.

The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.

Shyu WC, Pittman KA, Robinson DS, Barbhaiya RH.

Eur J Clin Pharmacol. 1993;45(6):559-62.

PMID:
8157043
12.

Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog.

Shukla UA, Kaul S, Marathe PH, Pittman KA, Barbhaiya RH.

Eur J Drug Metab Pharmacokinet. 1992 Oct-Dec;17(4):309-18.

PMID:
1301361
13.

Pharmacokinetics of nefazodone in the dog following single oral administration.

Shukla UA, Marathe PH, Labudde JA, Pittman KA, Barbhaiya RH.

Eur J Drug Metab Pharmacokinet. 1992 Oct-Dec;17(4):301-8.

PMID:
1301360
14.

The site of gastrointestinal absorption of gepirone in humans.

Tay LK, Dixon F Jr, Sostrin MB, Barr WH, Farmen RH, Pittman KA.

J Clin Pharmacol. 1992 Sep;32(9):827-32.

PMID:
1358923
15.

Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.

Shyu WC, Shah VR, Campbell DA, Wilber RB, Pittman KA, Barbhaiya RH.

J Clin Pharmacol. 1992 Sep;32(9):798-803.

PMID:
1430299
16.
17.

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Barbhaiya RH, Knupp CA, Pfeffer M, Zaccardelli D, Dukes GM, Mattern W, Pittman KA, Hak LJ.

Antimicrob Agents Chemother. 1992 Jul;36(7):1387-91. Erratum in: Antimicrob Agents Chemother 1992 Nov;36(11):2576.

18.

Lack of pharmacokinetic interaction between cefepime and amikacin in humans.

Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA.

Antimicrob Agents Chemother. 1992 Jul;36(7):1382-6.

19.

Effects of age and gender on pharmacokinetics of cefepime.

Barbhaiya RH, Knupp CA, Pittman KA.

Antimicrob Agents Chemother. 1992 Jun;36(6):1181-5.

20.

Effect of antacid on the bioavailability of cefprozil.

Shyu WC, Wilber RB, Pittman KA, Barbhaiya RH.

Antimicrob Agents Chemother. 1992 May;36(5):962-5.

21.

Excretion of cefprozil into human breast milk.

Shyu WC, Shah VR, Campbell DA, Venitz J, Jaganathan V, Pittman KA, Wilber RB, Barbhaiya RH.

Antimicrob Agents Chemother. 1992 May;36(5):938-41.

22.

Absolute bioavailability of cefprozil after oral administration in beagles.

Barbhaiya RH, Wang L, Shyu WC, Pittman KA.

Antimicrob Agents Chemother. 1992 Mar;36(3):687-9.

23.

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR.

Antimicrob Agents Chemother. 1992 Mar;36(3):552-7.

24.

Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.

Pai SM, Shukla UA, Grasela TH, Knupp CA, Dolin R, Valentine FT, McLaren C, Liebman HA, Martin RR, Pittman KA, et al.

J Clin Pharmacol. 1992 Mar;32(3):242-7.

PMID:
1564128
25.

Food-induced reduction in bioavailability of didanosine.

Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH.

Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):503-7.

PMID:
1934863
26.
28.

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, Barbhaiya RH.

Clin Pharmacol Ther. 1991 May;49(5):523-35.

PMID:
1903100
29.

Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment.

Shyu WC, Wilber RB, Pittman KA, Garg DC, Barbhaiya RH.

J Clin Pharmacol. 1991 Apr;31(4):372-6.

PMID:
2037711
30.

Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.

Shyu WC, Pittman KA, Wilber RB, Matzke GR, Barbhaiya RH.

J Clin Pharmacol. 1991 Apr;31(4):362-71.

PMID:
2037710
31.
32.

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA.

Drug Metab Dispos. 1991 Jan-Feb;19(1):68-73.

PMID:
1673424
33.

Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

Barbhaiya RH, Knupp CA, Tenney J, Martin RR, Weidler DJ, Pittman KA.

J Clin Pharmacol. 1990 Oct;30(10):900-10.

PMID:
2229450
34.

Pharmacokinetics of cefepime in subjects with renal insufficiency.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA.

Clin Pharmacol Ther. 1990 Sep;48(3):268-76.

PMID:
2401125
35.

Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1210-3.

36.

Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1204-9.

37.

Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Martin RR, Pittman KA.

Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203.

38.

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Martin RR.

Antimicrob Agents Chemother. 1990 Jun;34(6):1118-22.

39.
40.

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ.

Br J Clin Pharmacol. 1990 Apr;29(4):373-80.

41.

Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Barbhaiya RH, Gleason CR, Shyu WC, Wilber RB, Martin RR, Pittman KA.

Antimicrob Agents Chemother. 1990 Feb;34(2):202-5.

43.

Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl)piperazine in human plasma and urine by capillary gas chromatography-mass spectrometry.

Sciacca MA, Duncan GF, Shea JP, Faulkner HC 3rd, Farmen RH, Pittman KA.

J Chromatogr. 1988 Jul 15;428(2):265-74.

PMID:
3215930
44.

Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate.

Duncan GF, Faulkner HC 3rd, Farmen RH, Pittman KA.

J Pharm Sci. 1988 Mar;77(3):273-6.

PMID:
3286860
46.

Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.

Forgue ST, Shyu WC, Gleason CR, Pittman KA, Barbhaiya RH.

Antimicrob Agents Chemother. 1987 May;31(5):799-804.

47.

High-performance liquid chromatographic analysis of a novel carbapenem antibiotic in human plasma and urine.

Forgue ST, Pittman KA, Barbhaiya RH.

J Chromatogr. 1987 Mar 6;414(2):343-53.

PMID:
3571402
48.

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA.

Antimicrob Agents Chemother. 1987 Jan;31(1):55-9.

49.
50.

High-performance liquid chromatographic method for the determination of etoposide in plasma using electrochemical detection.

Duncan GF, Farmen RH, Movahhed HS, Pittman KA.

J Chromatogr. 1986 Aug 2;380(2):357-65.

PMID:
3760063

Supplemental Content

Loading ...
Support Center